AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32387542
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid (TT) vaccine
Trial: 33268022
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus Olanzapine
Trial: 33268022
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus Placebo
Trial: 35488323
Drug: G-CBT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CBT + usual care
Trial: 38975711
Drug: L-theanine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (200 mg)
Trial: 34726760
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (annual alcohol and other drugs awareness training only)
Trial: 34424869
Drug: Pregabalin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (2 mg/kg, twice daily preoperatively and for 5 days postoperatively)
Trial: 32094154
Drug: Community intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community intervention programme (three monthly community clinics treating wet cough with prolonged antibiotics)
Trial: 33676526
Drug: Ultra-congruent fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-congruent fixed (UC) implant
Trial: 33676526
Drug: Low congruent
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low congruent fixed (CR DD) implant
Trial: 33307633
Drug: Transversalis fascia
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversalis fascia plane (TFP) block with 0.4 mL/kg bupivacaine 0.25%
Trial: 32325778
Drug: Omega-3 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 and Vitamin D supplement (510 mg DHA, 344 mg EPA, 1000 IU vitamin D)
Trial: 35419807
Drug: ASP8302 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8302 (100 mg, oral, once daily for 4 weeks)
Trial: 35139809
Drug: Group transdiagnostic
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group transdiagnostic cognitive-behavioural therapy (tCBT)
Trial: 35139809
Drug: Individual transdiagnostic
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual transdiagnostic cognitive-behavioural therapy (tCBT)
Trial: 32841683
Drug: Porcine liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine liver decomposition product (PLDP) - 4 capsules for 4 weeks
Trial: 32841683
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 4 capsules for 4 weeks
Trial: 32281095
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine solution administered via new catheter
Trial: 33958243
Drug: Butorphanol in
RxNorm normalized name: butorphanol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol in combination with dexmedetomidine
Trial: 32443302
Drug: Dexmedetomidine-ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-ketamine (1 mg/kg ketamine, 1 μg/kg dexmedetomidine loading dose over 10 minutes, followed by infusion at 0.6 μg/kg/h for 20 minutes)
Trial: 32443302
Drug: Dexmedetomidine-fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine-fentanyl (1 μg/kg fentanyl, 1 μg/kg dexmedetomidine loading dose over 10 minutes, followed by infusion at 0.6 μg/kg/h for 20 minutes)
Trial: 32328824
Drug: G‐POEM (Gastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐POEM (Gastric peroral endoscopic myotomy)
Trial: 34018344
Drug: Mesdopetam (IRL790)
RxNorm normalized name: Mesdopetam
DrugBank: Mesdopetam (DB16229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesdopetam (IRL790) single dose (up to 120 mg)
Trial: 34018344
Drug: Mesdopetam (IRL790)
RxNorm normalized name: Mesdopetam
DrugBank: Mesdopetam (DB16229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesdopetam (IRL790) multiple doses (up to 80 mg)
Trial: 32192396
Drug: Oral agar
RxNorm normalized name: Agar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agar (600 mg/kg/day dissolved in 10 ml distilled water, twice daily until TSB decreased to 7 mg/dl)
Trial: 32192396
Drug: Oral agar
RxNorm normalized name: Agar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agar plus phototherapy
Trial: 32694374
Drug: EtOH ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtOH ingestion (0.1 g·kg lean body mass·h; 30.2 ± 1.1 g 40% ABV Vodka)
Trial: 35821785
Drug: Licaminlimab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licaminlimab (60 mg/mL ophthalmic solution)
Trial: 34345965
Drug: Viable probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viable probiotic tablets (Lactobacillus salivarius subsp. salicinius AP‐32, Bifidobacterium animalis subsp. lactis CP‐9, Lactobacillus paracasei ET‐66)
Trial: 34345965
Drug: Heat-killed probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed probiotic tablets (Lactobacillus salivarius subsp. salicinius AP‐32, Lactobacillus paracasei ET‐66)
Trial: 34201821
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug supplementation of ferrous sulfate associated with folic acid
Trial: 33572909
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) (n = 27) - continued daily lifestyle
Trial: 36281668
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy management
Trial: 34537624
Drug: Intranasal vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal vasopressin (AVP)
Trial: 34919219
Drug: Atorvastatin (oral)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (oral) after surgery for at least 1 week
Trial: 34919219
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no atorvastatin postoperatively)
Trial: 34477217
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of traditional and modern recruitment methods
Trial: 34106317
Drug: Oxymorphone (1.8,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone (1.8, 3.2, 5.6, 10, 18, 32 mg/70 kg)
Trial: 34106317
Drug: Hydromorphone (1.8,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (1.8, 3.2, 5.6, 10, 18 mg/70 kg)
Trial: 34106317
Drug: Oxycodone (18,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (18, 32, 56 mg/70 kg)
Trial: 34106317
Drug: Morphine (18,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (18, 32 mg/70 kg)
Trial: 32383277
Drug: Assay-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assay-guided treatment (AGT; N=151)
Trial: 32383277
Drug: Treatment-as-usual (TAU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU; N=153)
Trial: 33041038
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of a 1:1 fish to flaxseed oil supplement in colostrum
Trial: 33041038
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of a 1:1 fish to flaxseed oil supplement in colostrum
Trial: 33041038
Drug: 120 mL
RxNorm normalized name: 120 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mL of a 1:1 fish to flaxseed oil supplement in colostrum
Trial: 33041038
Drug: 0 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mL of a 1:1 fish to flaxseed oil supplement in colostrum (control group)
Trial: 33114566
Drug: Micronized lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized lipid‐based carotenoid supplement, Lumega‐Z (LM)
Trial: 33114566
Drug: PreserVision Age‐Related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PreserVision Age‐Related Eye Disease Study 2 (AREDS‐2) soft gel (PV)
Trial: 32677614
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) alone (0.1 mg/ml for 1 minute)
Trial: 36089222
Drug: 0.5% EGCG/ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% EGCG/ethanol solutions
Trial: 36131172
Drug: Heparin rota-flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin rota-flush solution
Trial: 36131172
Drug: Traditional rota-flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional rota-flush solution
Trial: 32848380
Drug: tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium 5 µg
Trial: 36036925
Drug: Vamorolone, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamorolone, 6 mg/kg per day
Trial: 36036925
Drug: Vamorolone, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamorolone, 2 mg/kg per day
Trial: 36036925
Drug: Prednisone, 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 0.75 mg/kg per day
Trial: 36036925
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including vamorolone and prednisone)
Trial: 35831153
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day
Trial: 35831153
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day and ezetimibe 10 mg/day (Control)
Trial: 32135208
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks (adults)
Trial: 32135208
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg or 300 mg every 2 weeks (adolescents)
Trial: 34215610
Drug: Implementation strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation strategy employing peer-led educational outreach, a clinical support tool, and peer support network to implement a TB treatment adherence intervention.
Trial: 32194058
Drug: HAT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAT therapy (hydrocortisone, ascorbic acid, thiamine)
Trial: 35587064
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy (control)
Trial: 36045304
Drug: TLPLDC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLPLDC vaccine
Trial: 34517775
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medication (PIM) use
Trial: 32474584
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors without appropriate indication
Trial: 32474584
Drug: Proton-Pump Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-Pump Inhibitors (PPIs) without appropriate indication
Trial: 35502947
Drug: Oral Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cannabidiol (CBD)
Trial: 34342172
Drug: Apixaban 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 0.5 mg IV
Trial: 34342172
Drug: Apixaban 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 1.25 mg IV
Trial: 34342172
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg IV
Trial: 34342172
Drug: Apixaban 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 3.75 mg IV
Trial: 34342172
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg IV
Trial: 34342172
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg oral
Trial: 33232555
Drug: Placebo (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose syrup)
Trial: 34916642
Drug: Conventional brain-guided
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional brain-guided (free-hand) implant surgery
Trial: 34916642
Drug: Dynamic computer-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic computer-assisted implant surgery (dCAIS)
Trial: 34916642
Drug: Static computer-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static computer-assisted implant surgery (sCAIS)
Trial: 34907003
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO2) therapy, ≥5 sessions (1 per day) for 90 minutes at 1.45 ATA for 7 days
Trial: 34907003
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for respiratory symptoms for 7 days
Trial: 33443079
Drug: Clazakizumab (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (25 mg, 4-weekly subcutaneous injections for 12 weeks)
Trial: 33443079
Drug: Clazakizumab (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (25 mg)
Trial: 34063083
Drug: Intermittent fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent fasting and glucose administration paired with relaxation and guided imagery
Trial: 36054786
Drug: Jaktinib 100
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaktinib 100 mg BID
Trial: 36054786
Drug: Jaktinib 200
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaktinib 200 mg QD
Trial: 33614436
Drug: Intravenous methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methadone
Trial: 32001844
Drug: General requirements,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General requirements, equipment, medicines and commodities, staffing and guidelines
Trial: 35182045
Drug: Roxadustat 200
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat 200 mg
Trial: 35182045
Drug: Roxadustat 200
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat 200 mg with simvastatin dosed 2 hours before, and 4 and 10 hours after
Trial: 35182045
Drug: Roxadustat 200
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat 200 mg with a statin
Trial: 35182045
Drug: Roxadustat 200
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat 200 mg with statins
Trial: 32398131
Drug: Integrated microfinance-group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated microfinance-group medical visit model for NCD, involving monthly group medical visits led by a community health educator and a rural clinician, tested over a 6-month pilot.
Trial: 33973398
Drug: Chiropractic care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic care and Exercise therapy (combined)
Trial: 38690606
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg daily
Trial: 35260464
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg two times a day)
Trial: 35260464
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (INR target 1.7-2.2)
Trial: 35260464
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg/day)
Trial: 34823375
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (exact dosage and duration not specified)
Trial: 38236314
Drug: Eptinezumab 100
RxNorm normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptinezumab 100 mg
Trial: 33023473
Drug: Eptinezumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptinezumab (both doses)
Trial: 34038904
Drug: Snail Soothing
RxNorm normalized name: Snail, unspecified
DrugBank: Snail, unspecified (DB14245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snail Soothing and Repairing (SSR) cream applied twice daily for 14 days
Trial: 34038904
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 14 days
Trial: 36484185
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (drugs, catheterization, bladder function rehabilitation training)
Trial: 34263648
Drug: Saffron total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron total glycoside tablets (four tablets each time, three times each day for 6 months)
Trial: 34263648
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four tablets each time, three times each day for 6 months)
Trial: 34263648
Drug: Saffron total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron total glycoside tablets
Trial: 33010240
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide 25 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Trial: 33010240
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Trial: 33010240
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg
Trial: 36209235
Drug: WGS-guided automated
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB
Trial: 36209235
Drug: RR-TB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RR-TB treatment according to the national South African guidelines
Trial: 32880493
Drug: Pulsed Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Radiofrequency (PRF) in addition to Transforaminal Epidural Steroid Injection (TFESI)
Trial: 32880493
Drug: Transforaminal Epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal Epidural Steroid Injection (TFESI) alone
Trial: 35147583
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with viral load >400 copies/mL
Trial: 32410827
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow-derived lineage-negative stem/progenitor cells (LIN- SPCs)
Trial: 33534266
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapy
Trial: 35632653
Drug: GamCOVIDVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GamCOVIDVac vaccine
Trial: 35632653
Drug: EpiVacCorona vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EpiVacCorona vaccine
Trial: 35632653
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific vaccine (prior to vaccination)
Trial: 36394933
Drug: Kombucha drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kombucha drink (KG), 220 ml, enriched with inulin (1.15 g/100 ml) for 10 days
Trial: 36394933
Drug: Water (Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (Control Group, CG), 220 ml for 10 days
Trial: 34587911
Drug: Beta-lactam antibiotics
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam antibiotics plus fluoroquinolones
Trial: 34587911
Drug: Beta-lactam antibiotics
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam antibiotics alone
Trial: 34571050
Drug: Rifaximin‐α (550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin‐α (550 mg BID)